Skip to main content
Top
Published in: Journal of General Internal Medicine 9/2019

01-09-2019 | Concise Research Reports

Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data

Authors: Inmaculada Hernandez, PharmD, PhD, William H. Shrank, MD, MSHS, Chester B. Good, MD, MPH, Walid F. Gellad, MD, MPH

Published in: Journal of General Internal Medicine | Issue 9/2019

Login to get access

Excerpt

Authorized generics—generic drugs that are simply relabeled versions of the original brand-name drug—are a mechanism by which manufacturers can voluntarily lower drug prices. Although evidence from the early 2000s suggests that authorized generics lower prices in the presence of other independent generics,1 the impact of authorized generics in markets with limited competition remains unknown. …
Literature
1.
go back to reference Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E. Authorized Generic Drugs, Price Competition, And Consumers’ Welfare. Health Aff (Millwood). 2007;26(3):790–9.CrossRef Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E. Authorized Generic Drugs, Price Competition, And Consumers’ Welfare. Health Aff (Millwood). 2007;26(3):790–9.CrossRef
Metadata
Title
Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data
Authors
Inmaculada Hernandez, PharmD, PhD
William H. Shrank, MD, MSHS
Chester B. Good, MD, MPH
Walid F. Gellad, MD, MPH
Publication date
01-09-2019
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 9/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-04989-6

Other articles of this Issue 9/2019

Journal of General Internal Medicine 9/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.